XBIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
725.3K
+9.8%
660.6K
-18.1%
806.9K
0
-100.0%
1.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
725.3K
+9.8%
660.6K
-18.1%
806.9K
0
-100.0%
1.0M
Operating Expenses
2.5M
+51.0%
1.6M
+24.7%
1.3M
-5.8%
1.4M
-11.6%
1.6M
R&D
520.7K
-5.7%
552.0K
-16.5%
661.4K
-14.5%
773.4K
+2.2%
756.5K
SG&A
1.9M
+79.9%
1.1M
+66.8%
647.6K
+5.1%
615.9K
-24.4%
815.2K
Operating Income
-1739152
-79.0%
-971690
-93.5%
-502117
+63.9%
-1389323
-155.0%
-544734
EBITDA
-1739152
-79.0%
-971690
-93.5%
-502117
+63.9%
-1389323
-155.0%
-544734
Net Income
-1695478
-82.4%
-929695
-103.7%
-456382
+21.2%
-579076
-13.6%
-509940
EPS (Basic)
$-0.72
-75.6%
$-0.41
-105.0%
$-0.20
+25.9%
$-0.27
+18.2%
$-0.33
EPS (Diluted)
$-0.72
-75.6%
$-0.41
-105.0%
$-0.20
+25.9%
$-0.27
+18.2%
$-0.33
Shares (Diluted)
2.3M
+2.1%
2.3M
+0.1%
2.3M
+5.1%
2.2M
+41.4%
1.5M
Xenetic Biosciences (XBIO) — Financials